Skip to main content

Prolexys Pharma and Whitehead Collaborate on Chemiproteomics

NEW YORK, Dec. 5 (GenomeWeb News) - Prolexys Pharmaceuticals, formerly Myriad Proteomics, announced today that it is collaborating with the Whitehead Institute to use compounds from Whitehead and Prolexys' HySpec mass spec platform and chemiproteomic techniques to find new oncology targets.

 

The collaboration will last for two years under the current agreement. Scientists will look to identify compounds with limited toxicology and side effects. Brent Stockwell's lab at Whitehead will provide the compounds and will modify the compounds following the proteomic studies at Prolexys.

 

Financial terms of the agreement were not disclosed.

 

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.